ReviewBiochemical pharmacology2009
RLIP76: A novel glutathione-conjugate and multi-drug transporter.
Review in Biochemical pharmacology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 57 citations in OpenAlex.
- RLIP76: a versatile ATP-dependent transporter as a pharmacotherapeutic target for epilepsy management.Inflammopharmacology · 2026Review
- Extracellular Matrix Microstructures Directly Regulate Glutathione Bioavailability in Human Hepatocytes.Biomacromolecules · 2025Article
- Cystine/Glutamate XcChemical research in toxicology · 2023Article
- CDDO-Me Attenuates CA1 Neuronal Death by Facilitating RalBP1-Mediated Mitochondrial Fission and 4-HNE Efflux in the Rat Hippocampus Following Status Epilepticus.Antioxidants (Basel, Switzerland) · 2022Article
- Anticancer Activity of Ω-6 Fatty Acids through Increased 4-HNE in Breast Cancer Cells.Cancers · 2021Article
- Activating p53 function by targeting RLIP.Biochimica et biophysica acta. Reviews on cancer · 2021Review
- Increased RLIP76 expression in IDH1 wild‑type glioblastoma multiforme is associated with worse prognosis.Oncology reports · 2020Article
- 2'-Hydroxyflavanone inhibits in vitro and in vivo growth of breast cancer cells by targeting RLIP76.Molecular carcinogenesis · 2018Article
- Metastasis of breast tumor cells to brain is suppressed by targeting RLIP alone and in combination with 2'-Hydroxyflavanone.Cancer letters · 2018Article
- RLIP76 Inhibition: A Promising Developmental Therapy for Neuroblastoma.Pharmaceutical research · 2017Review
- Targeting the mercapturic acid pathway and vicenin-2 for prevention of prostate cancer.Biochimica et biophysica acta. Reviews on cancer · 2017Review
- Review
- HNF1β drives glutathione (GSH) synthesis underlying intrinsic carboplatin resistance of ovarian clear cell carcinoma (OCCC).Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- Antioxidant role of glutathione S-transferases: 4-Hydroxynonenal, a key molecule in stress-mediated signaling.Toxicology and applied pharmacology · 2015Review
- RLIP76 Targeted Therapy for Kidney Cancer.Pharmaceutical research · 2015Review
- Article
- Overexpression of RLIP76 Required for Proliferation in Meningioma Is Associated with Recurrence.PloS one · 2015Article
- Glutathionylated products of lipid peroxidation: A novel mechanism of adipocyte to macrophage signaling.Adipocyte · 2014Article
- LIM kinase-2 induces programmed necrotic neuronal death via dysfunction of DRP1-mediated mitochondrial fission.Cell death and differentiation · 2014Article
- Glutathionylated 4-hydroxy-2-(E)-alkenal enantiomers in rat organs and their contributions toward the disposal of 4-hydroxy-2-(E)-nonenal in rat liver.Free radical biology & medicine · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
RLIP76, a stress-responsive, multi-functional protein with multi-specific transport activity towards glutathione-conjugates (GS-E) and chemotherapeutic agents, is frequently over-expressed in malignant cells. Our recent studies suggest that it plays a prominent anti-apoptotic role selectively in cancer cells. We have previously shown that RLIP76 accounts for up to 80% of the transport of GS-E and blocking the RLIP76-mediated transport of GS-E in cells results in the accumulation of pro-apoptotic endogenous electrophiles and on-set of apoptosis. Here we demonstrate that when RLIP76 mediate transport of GS-E is abrogated either by anti-RLIP76 IgG or accumulation of 4-hydroxynonenal (4-HNE) and its GSH-conjugate (GS-HNE) occurs and a massive apoptosis is observed in cells, indicate that the inhibition of RLIP76 transport activity at the cell surface is sufficient for observed anti-tumor activity. RLIP76 is linked with certain cellular functions including membrane plasticity and movement (as a primary 'effector' in the Ral pathway, perhaps functioning as a GTPase activating protein, or GAP), and as a component of clathrin-coated pit-mediated receptor-ligand endocytosis-a process that mediates movement of membrane vesicles.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.